MARKSANS PHARMA LTDLargo
Marksans Pharma Support Long Term
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. Its product portfolio spreads over major therapeutic areas such as oncology, gastroenterology, anti-diabetic, cardiovascular, pain management, and gynecology. The company was founded by Mark Bosco Saldanha on April 16, 1992 and is headquartered in Mumbai, India.
Buy at 70. Buy more at 50, 35
Target 100 for Short Term, 500 for Long Term
Duration 5 Years
Fundamental Snippets:
Market Cap - ₹ 2,837 Cr.
Current Price - ₹ 69.6
High / Low - ₹ 97.6 / 45.0
Stock P/E - 11.3
Book Value - ₹ 21.7
Dividend Yield - 0.36 %
ROCE - 38.9 %
ROE - 31.2 %
Face Value - ₹ 1.00
Debt to equity - 0.04
Price to book value - 3.20
PEG Ratio - 0.46
Promoter holding - 48.2 %
Change in Prom Hold - 0.00 %
Working capital - ₹ 629 Cr.
WC Days - 110
EVEBITDA - 7.40
Inven TO - 1.89
Current ratio - 3.30
Quick ratio - 1.82
Enterprise Value - ₹ 2,658 Cr.
EPS - ₹ 6.15
EPS preceding year - ₹ 2.95
Buy at 70. Buy more at 50, 35
Target 100 for Short Term, 500 for Long Term
Duration 5 Years
Fundamental Snippets:
Market Cap - ₹ 2,837 Cr.
Current Price - ₹ 69.6
High / Low - ₹ 97.6 / 45.0
Stock P/E - 11.3
Book Value - ₹ 21.7
Dividend Yield - 0.36 %
ROCE - 38.9 %
ROE - 31.2 %
Face Value - ₹ 1.00
Debt to equity - 0.04
Price to book value - 3.20
PEG Ratio - 0.46
Promoter holding - 48.2 %
Change in Prom Hold - 0.00 %
Working capital - ₹ 629 Cr.
WC Days - 110
EVEBITDA - 7.40
Inven TO - 1.89
Current ratio - 3.30
Quick ratio - 1.82
Enterprise Value - ₹ 2,658 Cr.
EPS - ₹ 6.15
EPS preceding year - ₹ 2.95
Publicaciones relacionadas
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.